This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Bilian Yu
the Second Xiangya Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background：In the recent outbreak of novel coronavirus infection worldwide, the risk of thrombosis and bleeding should be concerned.
Objectives: We aimed to observe the dynamic changes of D-dimer levels during disease progression to evaluate their value for thrombosis.
Methods: In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed.
Results: On admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-Dimer levels were higher in COVID-19 patients (P<0.05). Besides, we found that in COVID-19 patients, D-dimer were related with markers of inflammation, especially with hsCRP (R=0.426, P<0.05), and after treatments, D-dimer levels decreased which was synchronous with hsCRP levels in patients with good clinical prognosis, but there were still some patients with anomalous increasing D-dimer levels after therapy.
Conclusions: Elevated baseline D-dimer levels are associated with inflammation in COVID-19 patients, and the abnormal changes of D-dimer and inflammatory factors suggest that anticoagulant therapy might be needed.
Keywords
D-dimer, COVID-19, bacterial pneumonia, retrospective analysis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Journal of Thrombosis and Thrombolysis.
Version 1
Posted 31 Mar, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Bilian Yu
the Second Xiangya Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Journal of Thrombosis and Thrombolysis.
Version 1
Posted 31 Mar, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Journal of Thrombosis and Thrombolysis.
Background：In the recent outbreak of novel coronavirus infection worldwide, the risk of thrombosis and bleeding should be concerned.
Objectives: We aimed to observe the dynamic changes of D-dimer levels during disease progression to evaluate their value for thrombosis.
Methods: In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed.
Results: On admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-Dimer levels were higher in COVID-19 patients (P<0.05). Besides, we found that in COVID-19 patients, D-dimer were related with markers of inflammation, especially with hsCRP (R=0.426, P<0.05), and after treatments, D-dimer levels decreased which was synchronous with hsCRP levels in patients with good clinical prognosis, but there were still some patients with anomalous increasing D-dimer levels after therapy.
Conclusions: Elevated baseline D-dimer levels are associated with inflammation in COVID-19 patients, and the abnormal changes of D-dimer and inflammatory factors suggest that anticoagulant therapy might be needed.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...